Dashboard
Company has a low Debt to Equity ratio (avg) at 0.03 times
Positive results in Sep 26
Stock is technically in a Mildly Bearish range
With ROE of 17.8, it has a Expensive valuation with a 6.1 Price to Book Value
Increasing Participation by Institutional Investors
Underperformed the market in the last 1 year
Stock DNA
Healthcare Services
INR 2,092 Cr (Small Cap)
34.00
99
0.43%
-0.05
17.82%
6.13
Total Returns (Price + Dividend) 
Latest dividend: 2 per share ex-dividend date: Jun-18-2026
Risk Adjusted Returns v/s 
Returns Beta
News

Vimta Labs Ltd Technical Momentum Shifts Amid Mixed Indicator Signals
Vimta Labs Ltd, a small-cap player in the Healthcare Services sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a modest 1.03% gain on 20 Nov 2026, the stock’s technical indicators present a complex picture, reflecting both caution and potential opportunities for investors.
Read More
Vimta Labs Ltd Technical Momentum Shifts Amid Market Volatility
Vimta Labs Ltd, a small-cap player in the Healthcare Services sector, has experienced a notable shift in its technical momentum, reflecting a transition from a mildly bullish stance to a sideways trend. This change comes amid a sharp price correction and mixed signals from key technical indicators such as MACD, RSI, and moving averages, signalling a period of consolidation and uncertainty for investors.
Read More
Vimta Labs Ltd Upgraded to Hold by MarketsMOJO Amid Mixed Technical and Financial Signals
Vimta Labs Ltd, a small-cap player in the Healthcare Services sector, has seen its investment rating upgraded from Sell to Hold as of 16 Nov 2026. This change reflects a nuanced reassessment across four key parameters: quality, valuation, financial trend, and technicals. Despite recent underperformance relative to the broader market, the company’s improving financial metrics and stabilising technical indicators have prompted analysts to revise their outlook cautiously upward.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
04-Nov-2026 | Source : BSETranscript of the FY / Q2 - 2026-27 Earnings / Investor Call held on 30th October 2026.
Announcement under Regulation 30 (LODR)-Newspaper Publication
31-Oct-2026 | Source : BSENewspaper Publication of Unaudited Financial Results - Q2 FY 2026-27
Announcement under Regulation 30 (LODR)-Acquisition
30-Oct-2026 | Source : BSEIncorporation of a Wholly Owned Subsidiary in the United States of America (USA).
Corporate Actions 
No Upcoming Board Meetings
Vimta Labs Ltd has declared 100% dividend, ex-date: 18 Jun 26
Vimta Labs Ltd has announced 2:10 stock split, ex-date: 24 Feb 06
Vimta Labs Ltd has announced 1:1 bonus issue, ex-date: 13 Jun 25
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Non Institution
None
Held by 3 Schemes (0.23%)
Held by 40 FIIs (5.07%)
Sivalinga Prasad Vasireddi (11.63%)
Eurofins Analytical Services India Pvt Ltd (19.7%)
24.8%
Quarterly Results Snapshot (Standalone) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 2.67% vs -0.16% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is -2.04% vs -0.33% in Jun 2026
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 24.93% vs 14.97% in Sep 2024
Growth in half year ended Sep 2025 is 40.97% vs 56.87% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 19.44% vs 17.80% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 15.03% vs 81.53% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 18.41% vs 19.19% in Mar 2025
YoY Growth in year ended Mar 2026 is 15.10% vs 64.20% in Mar 2025